This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.

Inclusion Criteria:

• Patient has ovarian, primary peritoneal, or fallopian tube cancer
• Patient has first or subsequent relapse
• Patient has had at least on prior platinum-based treatment for ovarian cancer
• Patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or combination where one of the drugs is a platinum
• Patient is not pregnant

Exclusion Criteria:

• Patient has had abdominal surgery within the last 6 weeks
• Patient has life expectancy < 6 months
• Patient has had radiotherapy to the abdomen or pelvis within the last 6 months
• Patient has poorly controlled diabetes